drug

Roflumilast

MeSH C424423
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Takeda
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Investigational (via trials)
SchizophreniaSchizophrenia

Trials

1
Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
NCT02079844Phase 1Completed

KOLs & investigators

1
Medical Director Clinical Science

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Takeda
company
trial
Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
PHASE1
trial
indication
Schizophrenia
indication
Schizophrenia
indication
KOL
Medical Director Clinical Science
KOL score —
person